Medtronic, Inc. Earnings: Will Medical Devices Bounce Back?

Medtronic remains a leader in the medical-device industry, but spending trends have been poor. Will the market reverse itself?

May 16, 2014 at 6:30PM

Next Tuesday, Medtronic (NYSE:MDT) will release its quarterly report, and investors have recently sent shares of the medical-device giant to all-time record highs. Even though Medtronic and rivals Johnson & Johnson (NYSE:JNJ) and Boston Scientific (NYSE:BSX) have had to deal with rapid changes in the health-care industry, Medtronic hopes that some of the headwinds that have kept down revenue and earnings growth could finally dissipate in the near future, and that could help boost the stock even further.

Medtronic is a leader in the medical-device industry, with products ranging from cardiac pacemakers and defibrillators to stents, grafts, and other methods of supporting cardiovascular health. Yet with all the changes in health care associated with the implementation of the Affordable Care Act, Medtronic has had to adjust to budget pressures from some of its major health-care provider customers. Can Medtronic bounce back from that sluggishness? Let's take an early look at what's been happening with Medtronic over the past quarter and what we're likely to see in its report.

Mdt Pacemakers
Source: Medtronic.

Stats on Medtronic

Analyst EPS Estimate


Change From Year-Ago EPS


Revenue Estimate

$4.58 billion

Change From Year-Ago Revenue


Earnings Beats in Past 4 Quarters


Source: Yahoo! Finance.

What's next for Medtronic earnings?
Investors have been mostly stable in their views on Medtronic earnings in recent months, just clipping a single penny per share from their views for the 2015 fiscal year. The stock has kept climbing, with a rise of almost 7% since mid-February.

Medtronic's fiscal third-quarter report showed some of the challenges that the company faces in the current health-care environment. Revenue rose 3.4%, with emerging markets sales soaring 12% to help lift Medtronic's overall results. But adjusted net income dropped 3% due to the loss of tax incentives, costs from Obamacare, and a writedown related to the failure of a clinical trial. Those results are consistent with the difficulties that Boston Scientific and Johnson & Johnson have had in getting the growth they wanted from their respective medical-device businesses.

In particular, Medtronic has seen tough times lately in the cardiac rhythm management industry, as European sales have slowed and competition from Boston Scientific and other players has intensified. For its part, Medtronic has introduced smaller heart monitors to unlock new growth opportunities. But with Boston Scientific getting approval for new devices, Medtronic has to make sure its research and development efforts keep up with its peers in order to sustain its grip on the market.

Mdt Minimed

MiniMed 530G. Source: Medtronic.

But one area of great potential is Medtronic's diabetes division, which saw revenue jump 16% last quarter. With the introduction of its MiniMed 530G artificial pancreas system, Medtronic is focusing on a disease that has seen a huge rise in incidence. Johnson & Johnson is attempting to make an artificial pancreas that goes further than the MiniMed, but Medtronic's first-mover advantage could give it an important leg up in drawing and keeping new customers.

In the Medtronic earnings report, watch to see where the medical-device maker sees its greatest opportunities going forward. If the health-care industry finally loosens its purse strings and starts spending on equipment again, then Medtronic is in a good position to compete against Johnson & Johnson and Boston Scientific for its fair share of the resulting revenue.

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology’s true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Click here to add Medtronic to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson and Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers